Award
NIH Reporter #11380970
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
Recipient
Cognition Therapeutics, Inc.
Award Amount
$16,494,670.00
Ceiling
$16,494,670.00
Awarded
August 25, 2026
Identifier
11380970
A Phase 2 clinical trial funded by the National Institute on Aging to evaluate the safety and efficacy of CT1812 in early Alzheimer's disease over 18 months, awarded to Cognition Therapeutics, Inc.
Description
This is a Phase 2 clinical trial for Alzheimer's disease. The trial aims to evaluate the safety and efficacy of CT1812 over 18 months. The project is funded by the National Institute on Aging and conducted by Cognition Therapeutics, Inc.